Mode
Text Size
Log in / Sign up

Microscopic Polyangiitis

Part of Vasculitis

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Microscopic Polyangiitis

4 trials tracked for Microscopic Polyangiitis: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 132 citations.

4Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 2 Other / NA 1
  1. Phase 3 Rituximab Vasculitis Maintenance Study Completed · 132 cited
  2. Phase 4 Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Completed
  3. Phase 3 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed
  4. N/A An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Vasculitis

Related studies from across the Vasculitis family.

IL-5/IL-5Rα blockade provides clinically validated benefit in EGPA but requires phenotype-specific evidence for other conditions
Neurology Sys. Review
IL-5/IL-5Rα blockade provides clinically validated benefit in EGPA but requires phenotype-specific evidence for other conditions Targeting Eosinophils Shows Promise for Specific Autoimmune Conditions
This narrative review explores the role of eosinophils and IL-5/IL-5Rα and IL-4Rα blockade in various autoimmune diseases. The authors concl…
New research highlights how targeting specific immune cells like eosinophils can help manage certain inflammatory and autoimmune diseases.
Systematic review evaluates anti-IL-5 and anti-IL-5Rα biologics for eosinophilic respiratory and systemic diseases
Allergy & Immunology Sys. Review
Systematic review evaluates anti-IL-5 and anti-IL-5Rα biologics for eosinophilic respiratory and systemic diseases New Asthma Drugs Target the Real Troublemakers Hiding in Your Lungs
This systematic review examined the use of anti-IL-5 and anti-IL-5Rα biologics in patients with severe eosinophilic asthma, chronic rhinosin…
New asthma drugs target the specific immune cells causing swelling and mucus in severe asthma, nasal polyps, and rare eosinophil diseases.
Expert review outlines diagnostic and therapeutic management strategies for eosinophilic granulomatosis with polyangiitis
Pediatrics Sys. Review
Expert review outlines diagnostic and therapeutic management strategies for eosinophilic granulomatosis with polyangiitis Rare Lung and Blood Disease Gets a Smarter Treatment Map
This expert review addresses the management of patients with eosinophilic granulomatosis with polyangiitis (EGPA), focusing on glucocorticoi…
A new expert roadmap shifts treatment for rare EGPA disease from steroids to targeted biologic drugs for patients with stubborn asthma and o…

Questions about Microscopic Polyangiitis

How does the mortality risk for microscopic polyangiitis compare to granulomatosis with polyangiitis?

Microscopic polyangiitis (MPA) generally carries a higher mortality risk than granulomatosis with polyangiitis (GPA), with studies showing poorer survival and higher hazard ratios for death in MPA patients.

Full answer →